Anti-SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021

This study assesses how a limited supply of monoclonal antibody therapy was allocated to patients at highest risk of severe disease among a population of fee-for-service Medicare beneficiaries with a new COVID-19 diagnosis or confirmed exposure between November 2020 and August 2021.

Automated summary

This study assesses the allocation of limited monoclonal antibody therapy to the Medicare beneficiaries with the highest risk of severe COVID-19 among a population of fee-for-service patients between November 2020 and August 2021.